We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000938:SZSEUnisplendour Corporation Limited Analysis

Data as of 2026-05-22 - not real-time

CN¥29.86

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Unisplendour exhibits a classic bullish technical alignment with the 20‑day SMA (31.68) comfortably above the 50‑day (28.38) and 200‑day (26.84) averages, signaling upward momentum, yet the MACD histogram is negative and the signal line is bearish, suggesting short‑term weakness. The stock trades at a PE of 40.35, slightly above the industry average of 39.53, and a price‑to‑book of 5.5, indicating a premium valuation relative to peers. Financially, the company posts impressive revenue growth of 34.6% but operates on thin margins (gross 13.3%, operating 4.4%) and carries a hefty debt‑to‑equity ratio of 195%, with negative free cash flow, raising concerns about cash sustainability. Volume trends are decreasing, and 30‑day volatility is high at 56%, although beta is low, reflecting limited systematic risk but elevated idiosyncratic risk. Analysts maintain a “buy” consensus with a median target of ~33 CNY, implying roughly an 11% upside from the current price of 29.86 CNY, while the dividend yield is modest at 0.25% with a low payout ratio, questioning long‑term dividend reliability.
Given the mix of strong top‑line growth and sector tailwinds against a high‑cost structure, elevated debt, and premium valuation, the stock is best viewed as a growth‑oriented play that warrants cautious optimism. The technical bullish bias supports near‑term holding, but the bearish MACD and weakening volume suggest waiting for clearer momentum. Medium‑term fundamentals and analyst expectations provide upside potential, yet the heavy leverage and cash conversion issues temper enthusiasm for aggressive positioning. Long‑term investors should monitor debt reduction, cash flow improvement, and any regulatory shifts in China’s tech sector before committing fully.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA alignment but bearish MACD
  • Decreasing volume and high short‑term volatility
  • Current price near support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and analyst buy consensus
  • Potential ~11% upside to median target price
  • Sector tailwinds in AI and digital transformation

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity ratio and negative free cash flow
  • Premium valuation relative to peers
  • Regulatory uncertainty in China’s technology sector

Key Metrics & Analysis

Financial Health

Revenue Growth34.60%
Profit Margin2.04%
P/E Ratio40.4
ROE15.79%
ROA2.22%
Debt/Equity195.01
P/B Ratio5.5
Op. Cash FlowCN¥1.2B
Free Cash FlowCN¥-2061887360
Industry P/E39.5

Technical Analysis

TrendBullish
RSI47.4
SupportCN¥27.45
ResistanceCN¥34.49
MA 20CN¥31.68
MA 50CN¥28.38
MA 200CN¥26.84
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair ValueCN¥1.61
Target PriceCN¥33.20
Upside/Downside11.19%
GradeFair
TypeGrowth
Dividend Yield0.25%

Risk Assessment

Beta0.07
Volatility56.37%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.